Delving into the Latest Updates on Piperacillin Sodium/Tazobactam Sodium with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Piperacillin Sodium and Tazobactam Sodium, Piperacillin Sodium and Tazobactam Sodium (4:1), Piperacillin Sodium and Tazobactam Sodium(4:1)

+ [22]

Target

β-lactamase

Action

inhibitors

Mechanism

β-lactamase inhibitors(Beta Lactamase inhibitors)

Therapeutic Areas

Infectious DiseasesDigestive System DisordersHemic and Lymphatic Diseases+ [4]

Active Indication

Staphylococcal Skin InfectionsUlcerNeutropenia+ [24]

Inactive Indication

Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaCellulitis+ [8]

Originator Organization

Pfizer Inc.

Active Organization

Taiho Pharmaceutical Co., Ltd.Baxter Healthcare Corp.

B. Braun Medical, Inc.

+ [6]

Inactive Organization

Wyeth Pharmaceuticals LLCWyeth AB

License Organization-

Drug Highest PhaseApproved

First Approval Date

France (01 Jan 1992),

Bacterial InfectionsComplicated skin and soft tissue infectionHealthcare-Associated Pneumonia+ [4]

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC23H27N5NaO7S

InChIKeyHKKJNUJNRAREQR-IDYPWDAWSA-N

CAS Registry59703-84-3

View All Structures (2)

Norwegian guidelines for empirical antibiotic therapy in suspected community acquired sepsis recommend the combination of narrow spectrum betalactam and aminoglycoside as the first choice, but broad spectrum betalactams are considered equally appropriate, effective, and safe. However, fear of renal complications due to gentamicin and concern for lacking evidence for efficiency commonly leads to the use of broad spectrum betalactam therapy, a larger driver of antibiotic resistance.
In patients with suspected community acquired sepsis, the investigators hypothesize that empirical combination therapy with narrow spectrum betalactams and aminoglycosides is safe and non-inferior to empirical therapy with broad spectrum betalactams. More specifically, the investigators hypothesize that the proportion of patients with acute kidney injury or death will be similar between these two treatment groups. Furthermore, the investigators hypothesize that the aminoglycoside-based regimen has lesser impact on the gut microbiome. Antimicrobial resistance is one of the most urgent health threats of our time, and Norwegian hospitals were required but failed to reduce the use of broad-spectrum antibiotics with 30% by the end of 2020. In this context, novel initiatives aiming at reducing use of antibiotics are direly needed.

Start Date01 Oct 2025

Sponsor / Collaborator

Akershus Universitetssykehus HF

[+1]

NCT06954129

/ Not yet recruitingPhase 4IIT

Markers of Nephrotoxicity During Treatment With Antibiotic Combinations: A Pragmatic Clinical Trial

Hospitalized patients with suspected or confirmed infection are commonly treated with vancomycin (VN) in combination with either piperacillin-tazobactam (PT) or cefepime (CP). Although these regimens have similar effectiveness, recent observational evidence suggests they may differ in terms of the risk for acute kidney injury (AKI). Interpretation of existing evidence is complicated by the limitations of creatinine, the standard biomarker used to monitor kidney function, which has poor sensitivity and specificity for drug induced AKI. To address this important knowledge gap, the investigators propose to conduct a pragmatic, open-label, non-inferiority trial that will examine the comparative risk of AKI between these standard-of-care antibiotic combinations using sensitive and specific markers of drug-induced AKI. We hypothesize that the regimen of VN in combination with PT (VN+PT) is noninferior to the regimen of VN in combination with CP (VN+CP) in terms of AKI risk.

Start Date01 Oct 2025

Sponsor / Collaborator

University of Pennsylvania

ChiCTR2500109407

/ RecruitingEarly Phase 1IIT

A multicenter, prospective, randomized controlled trial evaluating β-lactam combined with omadacycline for the treatment of severe community-acquired pneumonia.

Start Date01 Sep 2025

Sponsor / Collaborator-

100 Clinical Results associated with Piperacillin Sodium/Tazobactam Sodium

Login to view more data

100 Translational Medicine associated with Piperacillin Sodium/Tazobactam Sodium

Login to view more data

100 Patents (Medical) associated with Piperacillin Sodium/Tazobactam Sodium

Login to view more data

4,669

Literatures (Medical) associated with Piperacillin Sodium/Tazobactam Sodium

01 Jan 2026·FOOD MICROBIOLOGY

Population structure of Bacillus cereus sensu lato associated with foodborne outbreaks in France between 2004 and 2023

Article

Author: Firmesse, Olivier ; Bonis, Mathilde ; Pairaud, Sylvie ; Mozhaitseva, Ksenia

Bacillus cereus sensu lato (Bcsl) is a group of closely related bacterial species known for their resistant spores, enabling them to persist in a dormant state and thereby colonize and adapt across diverse environments. Bcsl is known for its harmful impact on human health, producing toxins that cause emetic and diarrheal syndromes or provoking extradigestive infections. Importantly, Bcsl is the most frequent confirmed or presumptive causative agent associated with foodborne outbreaks (FBOs) in France. In our study, we assessed the population structure of a large collection of Bcsl isolated during FBOs investigation in France between 2004 and 2023, focusing on the association between distinct populations and food categories. Using 294 genomes from 183 FBOs, we applied genomic clustering and phylogenomic analysis and then identified three predominant Bcsl populations. B. cereus sensu stricto (17.0 %) prevailed in composite dishes, B. paranthracis (16.1 %) was positively associated with cereals, and B. thuringiensis subsp. kurstaki (7.6 %) was predominantly found in vegetable-based salads. Some strains were phylogenetically closely related to clinical isolates, highlighting the need to assess the antibiotic susceptibility of Bcsl. Notably, one Bcsl clade, B. cytotoxicus, lacking beta-lactamase-encoding genes showed a greatly increased sensitivity to ampicillin than other Bcsl considered to be naturally resistant to beta-lactams. Additionally, various strains from distinct populations showed reduced susceptibility to macrolides and cyclins. Finally, accurately differentiated populations will be used in further epidemiological studies and in dose-response modeling.

01 Dec 2025·JOURNAL OF CRITICAL CARE

Major publications in the critical care pharmacotherapy literature: 2024

Review

Author: Brown, Sophia ; Li, Ji ; Murray, Brian ; Farrar, Julie ; Roginski, Matthew A ; Bernardoni, Brittney ; Filiberto, Dina M ; Thompson, Tori R ; Perrodin, Jenna S ; Kopp, Brian J ; Esteves, Alyson M ; Madorsky, Melanie ; Tallon, Joanna K ; Moore, Megan J

OBJECTIVES:

To summarize, analyze, and provide clinical insights on the most impactful publications related to critical care pharmacotherapy in 2024.

METHODS:

A systematic search of PubMed/Medical Literature Analysis and Retrieval System Online (MEDLINE) was conducted between January 1, 2024, and December 31, 2024. Randomized controlled trials, prospective study designs, or retrospective study designs with high-quality methodology of adult critically ill patients assessing a pharmacotherapeutic intervention and reporting clinical endpoints were considered for inclusion. An a priori defined three-round modified Delphi process was performed to achieve consensus from a multi-disciplinary and geographically diverse group of critical care clinicians, focusing on the publications deemed most impactful based on their overall contribution to scientific knowledge and novelty.

RESULTS:

The systematic search yielded a total of 1533 articles, of which 1492 were excluded. Forty-one articles were included in the modified Delphi process. In each round, articles were independently scored based on their overall contribution to scientific knowledge and novelty and articles achieving a score at or above the median proceeded to the next round of voting. The six included articles are summarized and their impact is discussed. Article topics included cessation of proton pump inhibitors during transitions of care, stress ulcer prophylaxis in mechanically ventilated patients, continuous infusion beta-lactams in sepsis, ceftriaxone for prevention of ventilator-associated pneumonia, optimal antibiotic duration for bloodstream infections, and andexanet alfa for management of intracranial hemorrhage associated with factor Xa inhibitors.

CONCLUSIONS:

This review identified, summarized, and evaluated high impact studies relevant to critical care pharmacotherapy published in 2024.

01 Dec 2025·One Health

Unveiling the prevalence and antimicrobial resistance landscape of Pantoea genus in veterinary clinical strains: Insights from a cohort study

Article

Author: Caneiras, Cátia ; Bzdil, Jaroslav ; Holy, Ondrej ; Sladecek, Vladimir ; Zouharova, Monika ; Parra-Flores, Julio

The genus Pantoea, of which Pantoea agglomerans is the most common species, is an emerging Gram-negative facultative anaerobic bacillus that causes a wide range of opportunistic infections. To date, the prevalence, antibiotic resistance, and pathogenic potential of this bacterium in animals remains largely unexplored. The aim of this work was to describe the prevalence of microorganisms of the genus Pantoea in clinical samples obtained from animals during the period 2015-2017 and to define their susceptibility to antimicrobial agents. In the monitored period, a total of 23,739 clinical samples obtained from animals in the Czech Republic with symptoms of disease were tested, from which 151 Pantoea genus were isolated (prevalence 0.63 %). Cultivation and incubation were carried out under aerobic conditions by culture methods using massopeptone blood agar, Endo's agar and xylose lysine deoxycholate agar at 37 ± 1 °C for 24 h. Suspect strains were confirmed by matrix-assisted laser desorption/ionization coupled to time-of-flight mass spectrometry (MALDI-TOF MS). Susceptibility testing was performed by the standard disk diffusion method using Mueller-Hinton agar. Pantoea strains were recovered from domestic horses, carnivores (dogs, cats) and rodents (prevalence of 6.78, 1.64 and 1.12 % respectively). Resistance to beta-lactam antimicrobials was detected in 12 strains. In addition to beta-lactams, resistance to co-trimoxazole was detected in 1 case and to co-trimoxazole and chloramphenicol in 1 case, highlights the need to monitor the emergence of this strain in the context of the One Health approach.

18

News (Medical) associated with Piperacillin Sodium/Tazobactam Sodium

18 Dec 2024

·www.businesswire.com

Valink Therapeutics Appoints Biopharmaceutical Veteran Martin D. Williams as Chair of the Board of Directors and Names Scientific Advisory Board

BOSTON--( BUSINESS WIRE )--Valink Therapeutics, a biopharmaceutical company focused on discovering and developing innovative bispecific antibody-drug conjugates (bsADCs) to transform the treatment of cancer and other diseases, has appointed Martin D. Williams as Chair of its Board of Directors. The company also named its Scientific Advisory Board, which assembles experts in the discovery, development, manufacture and commercialization of ADCs and bispecific therapeutics. “ We are thrilled to welcome Martin, whose expertise in strategy, development and partnering, and track record of leading multiple U.S. biopharmaceutical companies, will be instrumental to the next stages of Valink. He brings deep experience advancing a wide range of therapeutics from early development through regulatory approval and commercialization and developing industry partnerships that move promising medicines closer to patients. Martin’s career journey, which began in the UK before his move to the U.S. over 30 years ago, mirrors Valink’s roots as a University of Oxford spinout based in the U.S., with a strong UK presence,” said Arne Scheu, DPhil, Co-founder and Chief Executive Officer of Valink. “ Furthermore, I am excited to announce our Scientific Advisory Board, which brings together a distinguished group of advisors who have been at the forefront of ADC and bispecific innovation and development.” Mr. Williams brings to Valink more than 35 years of experience in the global biopharmaceutical business, having closed more than $5 billion worth of corporate transactions, including numerous partnerships, M&A, and public and private financings. He recently served as Chief Executive Officer of Caraway Therapeutics, a venture-backed company developing therapeutics to modulate lysosomal function for neurodegenerative and rare diseases, through the company’s acquisition by Merck & Co. at the end of 2023. Previously, he was President and Chief Executive Officer of Tokai Pharmaceuticals, a clinical-stage oncology company; Chief Business Officer at Dicerna Pharmaceuticals, a leading RNAi company with programs in oncology; and Chief Business Officer and Senior Vice President for commercial and business development at Synta Pharmaceuticals, a clinical-stage public company focused on oncology and inflammation. Earlier in his career, he held various leadership positions and directed the development, commercialization and launch of several flagship brands for GSK, Hoffmann-La Roche and Lederle/Wyeth (now Pfizer), including GSK’s blockbusters Zantac® and Zofran®; Hoffmann La-Roche’s Xenical®; and Lederle/Wyeth’s global anti-infective portfolio, including Zosyn®/Tazocin®. He holds an MBA from Harvard Business School and an MS from the University of Manchester, UK. “ Valink has developed a compelling approach to realizing the unmet potential of ADCs to improve outcomes for patients with cancer and other diseases, which has been restricted by dose-limiting toxicities and the range of suitable targets. Their technology addresses a significant challenge to ADC innovation by enabling rapid and cost-effective generation and screening of bispecific ADCs, unlocking a vast range of target synergy and potentially bringing previously undruggable space within reach,” said Mr. Williams. “ I am excited to work closely with the Valink executive team and Board as the company builds on its discoveries and pursues its clinical aspirations.” Valink also announced the formation of its Scientific Advisory Board, initially consisting of: Sonia Quaratino, MD, PhD is Executive Vice President and Chief Medical Officer at Innate Pharma, a clinical-stage biotech utilizing monoclonal antibodies, multi-specific NK cell engagers and ADCs to develop immunotherapies for cancer. Her career spans over 25 years in basic research, clinical development and translational medicine across academia, biotech and global pharmaceuticals. She has held numerous leadership positions, including serving as CMO at Kymab (until its acquisition by Sanofi) and Georgiamune Inc, and was Professor of Immunology at the University of Southampton. Marc Damelin, PhD is Chief Scientific Officer at Alphina Therapeutics and an expert in oncology drug discovery and development. Previously he served as VP and Head of Biology at Mersana Therapeutics, a clinical-stage biotech developing ADCs to treat cancer. Prior to that he worked for a decade in ADC discovery and development in Pfizer's Oncology Research Unit. Robert Lutz, PhD , Chief Scientific Officer at leading ADC company Iksuda Therapeutics, is a recognized expert in ADC discovery and development. As VP of Translational R&D at ImmunoGen, he was responsible for bringing eight ADC product candidates into development and was the research lead for Kadcyla®, the first ADC to be approved for solid tumor indications. Antoine Awad , Principal Executive Officer of Synlogic, has extensive experience in CMC, bispecific drug development and partnerships. Prior to Synlogic, he held leadership positions at various biotechs, including Merrimack Pharmaceuticals, where he led CMC development, manufacturing and approval of ONIVYDE® for treatment of advanced pancreatic cancer and transitioned to Ipsen Bioscience to lead global commercial manufacturing of ONIVYDE®. Mihriban Tuna, PhD is Chief Executive Officer of Immutrin and Entrepreneur-in-Residence at Cambridge Innovation Capital, a leading UK-based venture company focused on deep tech and life sciences. She previously served as Chief Scientific Officer at Adaptate Biotherapeutics (acquired by Takeda) and SVP, Drug Discovery at F-star Therapeutics, and was an early employee at Domantis Ltd. (acquired by GSK). Alexey A. Lugovskoy, PhD is President and Chief Executive Officer of Diagonal Therapeutics, Entrepreneur-in-Residence at Atlas Ventures and Associate Editor of mAbs . He formerly served as Chief Operating Officer at Dragonfly, Chief Development Officer at Morphic, Vice President of Therapeutics at Merrimack Pharmaceuticals and Associate Director of Drug Discovery at Biogen. He joined Valink’s Board of Directors in 2023, and this additional appointment highlights a close collaboration between the Scientific Advisory Board, Board of Directors and leadership team. About Valink Therapeutics Valink Therapeutics Inc. is a biopharmaceutical company focused on the discovery and development of first-in-class bispecific antibody-drug conjugates (bsADCs) to transform the treatment of cancer and other diseases. Valink’s technology platform utilizes a modular assembly approach to rapidly generate bsADCs with therapeutic potential, testing drugs at unparalleled scale and speed to improve on the payload delivery and selectivity of conventional ADCs. The company is based in Boston, Massachusetts and has research and development operations in London, UK. For more information, visit the company’s website at www.valinktx.com or contact the company at connect@valinktx.com .

Executive ChangeADCAcquisitionDrug Approval

28 Jun 2024

·www.pharmaindustrial-india.com

Orchid Pharma and Cipla to Launch Cefepime-Enmetazobactam in India

Orchid Pharma has launched its new drug, Cefepime-Enmetazobactam, which has been approved for the treatment of complicated Urinary Tract infections (cUTI), Hospital-Acquired Pneumonia (HAP) and Ventilator-Associated Pneumonia (VAP) indications. In a landmark collaboration, Orchid Pharma has partnered with Cipla to ensure widespread and rapid distribution of this breakthrough antibiotic combination across India. The launch of Cefepime-Enmetazobactam marks a significant milestone for India's pharmaceutical industry in the fight against AMR, a growing global health issue, reinforcing India’s leadership in medical innovation. Orchid Pharma and Cipla are confident that this collaboration will set a new benchmark for addressing critical healthcare challenges through strategic partnerships and advanced research. The partnership between Orchid Pharma and Cipla combines Orchid's innovative drug development capabilities with Cipla's extensive distribution network and market presence. This collaboration aims to ensure that this life-saving medication reaches healthcare providers across India as quickly and efficiently as possible. Speaking on the launch, Manish Dhanuka, Managing Director Orchid Pharma said, "With increasing resistance to the current drugs most commonly used for treatment of these indications, e.g., Piperacillin-Tazobactam for cUTI – doctors were forced to start using Carbapenems – a reserve drug meant to be used when most other drugs don't work. Now, Orchid's Cefepime- Enmetazobactam will allow doctors to spare Carbapenems, prolonging their effective life by restricting their use." Umang Vohra, Managing Director & Global Chief Executive Officer, Cipla, said, “AMR is an urgent and serious healthcare challenge that needs global attention. With the rising incidence of potentially threatening infections, there is a strong need for novel anti-infectives in the effective treatment of MDR infections. This partnership enhances Cipla’s commitment to AMR stewardship and strengthens our efforts to combat infectious diseases and deliver advanced, innovative therapies to patients.” Both companies are committed to responsible antibiotic stewardship and will work closely with healthcare professionals to ensure the appropriate use of this new antibiotic combination. Educational initiatives and guidelines for prescribing will be developed to maximize the drug's benefits while minimizing the risk of further antimicrobial resistance.

Drug Approval

13 May 2024

·www.sciencedaily.com

Commonly used antibiotic brings more complications, death in the sickest patients

Treatment with the commonly used antibiotic piperacillin/tazobactam was associated with a 5 percent increase in 90-day mortality, more days on a ventilator, and more time with organ failure for patients with sepsis, finds a new study. In emergency rooms and intensive care units across the country, clinicians make split-second decisions about which antibiotics to give a patient when a life-threatening infection is suspected. A new U-M study reveals that these decisions may have unintended consequences for patient outcomes. Beginning in 2015, a 15-month national shortage of a commonly prescribed antibiotic, piperacillin/tazobactam, known by the brand name Zosyn, provided a unique opportunity to compare rates of death in hospitalized patients with sepsis who were administered two different types of antibiotics -- one that spares the gut microbiome and one that profoundly alters it. Piperacillin/tazobactam is a broad-spectrum antibiotic that is commonly administered for sepsis, a life-threatening complication from infection. In its absence, clinicians commonly instead use another antibiotic, cefepime, which has similar activity against common sepsis pathogens but, unlike piperacillin/tazobactam, has minimal effects on anaerobic gut bacteria. "We saw this Zosyn shortage as a one-of-a-kind opportunity to ask whether this antibiotic, which we know depletes the gut of anaerobic bacteria, makes a difference in terms of patient outcomes," said Robert Dickson, M.D. of the Department of Medicine's Division of Pulmonary & Critical Care Medicine and Deputy Director of the Weil Institute for Critical Care Research & Innovation. In health, the gut microbiome is largely populated by anaerobic bacteria that rarely cause disease. Prior work by the study team has revealed that even a single dose of piperacillin/tazobactam kills most of these anaerobic gut bacteria, which play important roles in the body's metabolism, immunity, and prevention of infections. Dickson, Rishi Chanderraj, M.D. of the Division of Infectious Disease, Michael Sjoding, M.D. of the Division of Pulmonary & Critical Care Medicine and their multidisciplinary team at U-M and the VA Ann Arbor used patient record data to look at outcomes in 7,569 patients. The team compared 4,523 patients who were treated were piperacillin/tazobactam with 3,046 patients who received cefepime. They found marked differences: treatment with piperacillin-tazobactam was associated with a 5 percent increase in 90-day mortality, more days on a ventilator, and more time with organ failure. "These are powerful antibiotics that are administered to patients every day in every hospital nationwide," said Chanderraj. "Clinicians use them because they are trying to treat every possible pathogen that might be causing their patients' illness. But our results suggest that their effects on the microbiome might also have important effects on patient outcomes." The study builds on previous work by the study team that suggested critically ill patients may do worse when given antibiotics that deplete the gut of anaerobes. They have also seen similar effects when studying animal models. "Our prior work suggested that there might be harm with piperacillin/tazobactam, but it was an observational study that had some limitations," said Sjoding, the study's senior author. "That's why the drug shortage was such an amazing opportunity. It created an almost perfect natural experiment that let us test the difference between these two drugs on patient outcomes in a very rigorous manner." A recent clinical trial pitted these two antibiotics against each other and compared side effects and mortality after two weeks. That trial did not find any differences in the short term -- a finding that the U-M team also observed in their analysis. "When we looked at two-week outcomes in our study, we didn't find differences either," said Chanderraj. "But the differences at three months were dramatic." Overall, the new findings suggest that treatment with piperacillin/tazobactam instead of cefepime may contribute to one additional death per every 20 septic patients treated. "A 5% mortality difference has enormous implications because sepsis is so common," said Dickson. "Every day, thousands of clinicians are deciding which of these drugs to use in septic patients." Physicians should give more thought about whether anti-anerobic antibiotics are warranted before prescribing them, added Chanderraj. "We need to think about antibiotics like chemotherapy. In the right context, treatment can be lifesaving, but in the wrong context, it can be quite harmful."

Clinical Result

100 Deals associated with Piperacillin Sodium/Tazobactam Sodium

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	Piperacillin Sodium/Tazobactam Sodium	J01CR05	-

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Pelvic Infection	United States	Wyeth Pharmaceuticals LLC	26 May 2020
Staphylococcal Skin Infections	Japan	Taiho Pharmaceutical Co., Ltd.	18 May 2017
Ulcer	Japan	Taiho Pharmaceutical Co., Ltd.	18 May 2017
Neutropenia	Japan	Taiho Pharmaceutical Co., Ltd.	26 Jun 2015
Abdominal Abscess	Japan	Taiho Pharmaceutical Co., Ltd.	28 Sep 2012
Cholangitis	Japan	Taiho Pharmaceutical Co., Ltd.	28 Sep 2012
Cholecystitis	Japan	Taiho Pharmaceutical Co., Ltd.	28 Sep 2012
Gynecological infection	Australia	Sandoz Pty Ltd.	10 Dec 2008
Lower Respiratory Tract Infections	Australia	Sandoz Pty Ltd.	10 Dec 2008
Sepsis	Australia	Sandoz Pty Ltd.	10 Dec 2008
Urinary Tract Infections	Australia	Sandoz Pty Ltd.	10 Dec 2008
Cystitis	Japan	Taiho Pharmaceutical Co., Ltd.	16 Jul 2008
Hemorrhagic Septicemia	Japan	Taiho Pharmaceutical Co., Ltd.	16 Jul 2008
Pyelonephritis	Japan	Taiho Pharmaceutical Co., Ltd.	16 Jul 2008
Endometritis	United States	Baxter Healthcare Corp.	06 May 2003
Community Acquired Pneumonia	United States	Baxter Healthcare Corp.	24 Feb 1998
Abscess	United States	Wyeth Pharmaceuticals LLC	22 Oct 1993
Appendicitis	United States	Wyeth Pharmaceuticals LLC	22 Oct 1993
Cellulitis	United States	Wyeth Pharmaceuticals LLC	22 Oct 1993
Diabetic Foot	United States	Wyeth Pharmaceuticals LLC	22 Oct 1993

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Acute Lymphoblastic Leukemia	Phase 3	United States	Wyeth AB	06 Sep 2002
Acute Lymphoblastic Leukemia	Phase 3	Canada	Wyeth AB	06 Sep 2002
Acute Myeloid Leukemia	Phase 3	United States	Wyeth AB	06 Sep 2002
Acute Myeloid Leukemia	Phase 3	Canada	Wyeth AB	06 Sep 2002
Chronic Lymphocytic Leukemia	Phase 3	United States	Wyeth AB	06 Sep 2002
Chronic Lymphocytic Leukemia	Phase 3	Canada	Wyeth AB	06 Sep 2002
Chronic Myelomonocytic Leukemia	Phase 3	United States	Wyeth AB	06 Sep 2002
Chronic Myelomonocytic Leukemia	Phase 3	Canada	Wyeth AB	06 Sep 2002
Chronic phase chronic myeloid leukemia	Phase 3	United States	Wyeth AB	06 Sep 2002
Chronic phase chronic myeloid leukemia	Phase 3	Canada	Wyeth AB	06 Sep 2002

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ATS2025	Not Applicable	Leukopenia	-	Piperacillin-Tazobactam	jasvgklacv(fyxuwyxvgr): OR = 0.51, P-Value = < 0.001	Positive	16 May 2025
				Cefepime
NCT05753735 (CTgov)	Phase 2	Pancreatic Fistula	3	Piperacillin/Tazobactam (Standard Perioperative Antibiotics)	ffnjjiktwi(yiizcasdgn) = podlnpnyis nlbpumkqmr (hnfqqegiqg, ldqgjytois - rugaardrex) View more	-	24 Sep 2024
				Piperacillin/Tazobactam+Amoxicillin/ Clavulanic acid (Extended Antibiotic Prophylaxis)	kvtxdiuape = uuldkjdpjl fvjvejclvw (wbqzshirrl, mnbeooexcu - ohkqexuouh) View more
NCT03289351 (CTgov)	Phase 4	Postoperative infection \| Appendicitis	162	metronidazole+ceftriaxone (2-drug Therapy)	vcqwvcgdec = ocrtkigluf yuqjoxnwcw (exdnmanbhs, luaitsjurf - mnipdbbkxr) View more	-	12 Jan 2024
				Piperacillin, Tazobactam Drug Combination (1-drug Therapy)	vcqwvcgdec = mfhmjysutd yuqjoxnwcw (exdnmanbhs, peuzxgsphf - ahiiaowyjv) View more
NCT05102162 (CTgov)	Phase 4	Pneumonia	35	Meropenem+Piperacillin/Tazobactam+Cefepime (Continuous Antibiotic Dose Over 24 Hours Arm)	dluxsyvilc = mppqtmdjbz zmrzkkmeci (moqxfemxgv, somujebyfb - wweeywyjfp) View more	-	12 Dec 2023
				Meropenem+Piperacillin/Tazobactam+Cefepime (Intermittent Antibiotic Dose Over 30 Minutes)	dluxsyvilc = vzgwpfgqon zmrzkkmeci (moqxfemxgv, pjgpwsrrup - bzsodxmbjh) View more
NCT03269994 (Pubmed)	Phase 3	-	778	Piperacillin-Tazobactam	imzetxqput(irgtrqaoyn) = boarzahkpj pynejwzfud (fpclxhecwd )	-	20 Apr 2023
				Cefoxitin	imzetxqput(irgtrqaoyn) = baszfodnot pynejwzfud (fpclxhecwd )
NCT01694069 (PIPE-CF, CTgov)	Phase 4	Cystic Fibrosis	6	Piperacillin-tazobactam combination product (Intermittent Infusion Piperacillin-tazobactam)	bolyusjwcz(xjzfbnxhng) = xphbwltmks szyzyfvjfz (qtakgjakod, slzjxiftci - rxozvrdiud) View more	-	01 Feb 2022
				Piperacillin-tazobactam combination product (Continuous Infusion Piperacillin-tazobactam)	bolyusjwcz(xjzfbnxhng) = zgykjgvzro szyzyfvjfz (qtakgjakod, xghqqrsdzl - lrmotkowyu) View more
NCT02991937 (CTgov)	Phase 4	Appendicitis	39	Piperacillin/Tazobactam (Medical Therapy)	wuxuydbvcw(dgimavrxgb) = rlgkpaxqyc tugwyeuxzg (zplpgtqsyd, mybgzeylcd - xmvxhhrhnu) View more	-	21 Jan 2022
				Surgical Treatment+Piperacillin/Tazobactam (Surgical Intervention)	wuxuydbvcw(dgimavrxgb) = gizyiddkok tugwyeuxzg (zplpgtqsyd, heueegwolu - rewawcdnom) View more
NCT03019965 (CTgov)	Not Applicable	Sepsis	426	Meropenem+Imipenem+Piperacillin+Tazobactam (Intermittent. Piperacillin/Tazobactam, Imipenem, Meropenem)	fgojnstotn = pbwqqgdfzo bdqrqgxrxf (jezwsirxqh, cllyeapvmh - gtioejestu) View more	-	05 Aug 2021
				Meropenem+Imipenem+Piperacillin+Tazobactam (Prolonged Infusion. Continuous Piperacillin/Tazobactam, Extended Imipenem, Extended Meropenem)	fgojnstotn = aqubosravh bdqrqgxrxf (jezwsirxqh, newdlugikv - iuugaakuxa) View more
NCT01923363 (CTgov)	Not Applicable	Obesity	29	Piperacillin/Tazobactam Standard Dose to High Dose	ydaozkafrp(tekjzazaai) = tejjfgkije rsxrnbjner (owuwpgvcxz, zqpzqapovm - enwfmnzyxe) View more	-	26 Oct 2018
NCT02176122 (Pubmed \| JAMA) Manual	Phase 4	Sepsis \| Escherichia Coli Infections	379	Piperacillin-Tazobactam	qwmnuooxmt(smrfofltsb) = obnajisvqt rsvutpxpfn (uzkechztam ) View more	Negative	11 Sep 2018
				Meropenem	qwmnuooxmt(smrfofltsb) = itubxadufz rsvutpxpfn (uzkechztam ) View more